|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
tyrosine kinase inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Iclusig
|
|
gptkbp:clinical_trial
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to ponatinib
|
|
gptkbp:developed_by
|
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:dosage_form
|
15 mg once daily
30 mg once daily
|
|
gptkbp:effective_date
|
gptkb:2013
|
|
gptkbp:excretion
|
bile
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ponatinib
|
|
gptkbp:indication
|
gptkb:Philadelphia_chromosome-positive_leukemia
|
|
gptkbp:ingredients
|
C24 H26 Cl N7 O2 S
|
|
gptkbp:interacts_with
|
strong CY P3 A4 inducers
strong CY P3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L01 X E30
|
|
gptkbp:is_monitored_by
|
cardiac function
blood pressure
blood counts
|
|
gptkbp:is_used_for
|
gptkb:chronic_myeloid_leukemia
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
approximately 24 hours
|
|
gptkbp:market
|
gptkb:stock_market_index
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:safety_features
|
risk of heart failure
risk of bleeding
risk of arterial thrombosis
risk of hepatotoxicity
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
hypertension
diarrhea
rash
cardiovascular events
thrombosis
pancreatitis
musculoskeletal pain
|
|
gptkbp:status
|
ongoing studies
|
|
gptkbp:targets
|
gptkb:BCR-ABL_fusion_protein
|
|
gptkbp:treatment
|
not typically used
used after other treatments fail
|
|
gptkbp:type_of
|
943319-65-1
|
|
gptkbp:bfsParent
|
gptkb:Iclusig
|
|
gptkbp:bfsLayer
|
5
|